Continuation of Research and Development Activities
First written in FY2016-Q2. 29 of 34 entries say "Restated". Latest entry: FY2026-H1.
96 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the six-month interim consolidated accounting period were ¥67.785 million. The Group's R&D activities were otherwise materially unchanged during the six-month interim consolidated accounting period.」
R&D expenses of ¥67.785 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2025RestatedAnnual report
「This business segment concentrates its R&D efforts in 3 areas: seedlings, breeding, and vaccines. While making new efforts toward sustainable agriculture for the future, it focuses primarily on improving seedling productivity and quality and adding value.」
The policy of concentrating R&D in 3 areas—seedlings, breeding, and vaccines—to improve productivity, quality, and added value is continuing. R&D expenses were ¥109.914 million. - FY2024-Q2RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first six months of the fiscal year were ¥57.357 million. The Group's R&D activities were otherwise materially unchanged during the first six months of the fiscal year.」
R&D expenses of ¥57.357 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first three months of the fiscal year were ¥22.612 million. The Group's R&D activities were otherwise materially unchanged during the first three months of the fiscal year.」
R&D expenses of ¥22.612 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2023AdvancedAnnual report
「This business segment concentrates its R&D efforts in 3 areas: seedlings, breeding, and vaccines. While making new efforts toward sustainable agriculture for the future, with improving seedling productivity and quality and adding value as its primary research themes, it has established cooperative frameworks with universities and public research institutions for the development and dissemination of seedlings. By sharing research data and exchanging views, it has created a framework for rapidly applying research results at production sites, strengthening coordination between the R&D and production divisions and leading to higher productivity and labour savings.」
R&D priorities were organised into 3 areas—seedlings, breeding, and vaccines—and a framework for transferring research results to production sites was developed. R&D expenses were ¥102.168 million. - FY2023-Q3RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first nine months of the fiscal year were ¥76.580 million. The Group's R&D activities were otherwise materially unchanged during the first nine months of the fiscal year.」
R&D expenses of ¥76.580 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2023-Q2RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first six months of the fiscal year were ¥53.216 million. The Group's R&D activities were otherwise materially unchanged during the first six months of the fiscal year.」
R&D expenses of ¥53.216 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2023-Q1RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first three months of the fiscal year were ¥21.850 million. The Group's R&D activities were otherwise materially unchanged during the first three months of the fiscal year.」
R&D expenses of ¥21.850 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2022RestatedAnnual report
「As a vegetable seedling producer, the Group continues R&D activities aimed at developing cutting-edge seedling production technologies and resolving issues with existing technologies. It is also actively pursuing the development of new seedlings using its seedling production technologies, joint breeding and variety-improvement trials with affiliated companies, technology development for expanding its seedling business overseas, and verification trials to identify and develop new products.」
R&D and technology development, breeding and variety improvement, overseas expansion, and verification of new products are continuing. R&D expenses were ¥95.463 million. - FY2022-Q3RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first nine months of the fiscal year were ¥70.796 million. In the vegetable seedling and related business, the Plant Vaccine Comprehensive Research Institute was completed at consolidated subsidiary ベルグ福島株式会社, and R&D began on plant vaccines and the commercialisation of vaccine-treated seedlings.」
R&D expenses of ¥70.796 million were recorded, and R&D is continuing at the Plant Vaccine Comprehensive Research Institute of ベルグ福島. - FY2022-Q2AdvancedAnnual report
「In the vegetable seedling and related business, the Plant Vaccine Comprehensive Research Institute was completed at consolidated subsidiary ベルグ福島, and R&D began on plant vaccines and the commercialisation of vaccine-treated seedlings.」
The Plant Vaccine Comprehensive Research Institute was completed at ベルグ福島, and R&D began on plant vaccines and vaccine-treated seedlings. - FY2022-Q1RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first three months of the fiscal year were ¥13.728 million. The Group's R&D activities were otherwise materially unchanged during the first three months of the fiscal year.」
R&D expenses of ¥13.728 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2021AdvancedAnnual report
「Beginning in the fiscal year ending October 2022, we also began full-scale development of plant vaccines at consolidated subsidiary ベルグ福島. Plant vaccines are expected to enable effective pest and disease control without reliance on chemical pesticides, environmentally responsible and stable production, and improved quality, and we are confident that they can contribute to the future of Japanese agriculture.」
Plant vaccine development was added to the R&D activities, with plans for full-scale development beginning in the fiscal year ending October 2022. - FY2021-Q3RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first nine months of the fiscal year were ¥62.706 million. The Group's R&D activities were otherwise materially unchanged during the first nine months of the fiscal year.」
R&D expenses of ¥62.706 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2021-Q2RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first six months of the fiscal year were ¥42.471 million. The Group's R&D activities were otherwise materially unchanged during the first six months of the fiscal year.」
R&D expenses of ¥42.471 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2021-Q1RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first three months of the fiscal year were ¥18.957 million. The Group's R&D activities were otherwise materially unchanged during the first three months of the fiscal year.」
R&D expenses of ¥18.957 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2020-Q3RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first nine months of the fiscal year were ¥57.923 million. The Group's R&D activities were otherwise materially unchanged during the first nine months of the fiscal year.」
R&D expenses of ¥57.923 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2020-Q2RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first six months of the fiscal year were ¥39.743 million. The Group's R&D activities were otherwise materially unchanged during the first six months of the fiscal year.」
R&D expenses of ¥39.743 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2020-Q1RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first three months of the fiscal year were ¥16.891 million. The Group's R&D activities were otherwise materially unchanged during the first three months of the fiscal year.」
R&D expenses of ¥16.891 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2019RestatedAnnual report
「As a vegetable seedling manufacturer, the Group continues to conduct research and development aimed at developing advanced seedling cultivation technologies and resolving issues with existing technologies.」
R&D expenses were ¥75.857 million. Research continued in areas including environmental monitoring, closed-system seedling production, new equipment, grafted seedlings with pest and disease control properties, and selection technologies for affiliated companies and overseas varieties. - FY2019-Q3RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first nine months of the fiscal year were ¥53.512 million. The Group's R&D activities were otherwise materially unchanged during the first nine months of the fiscal year.」
R&D expenses of ¥53.512 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2019-Q2RestatedAnnual report
「The total R&D expenses included in selling, general and administrative expenses and current manufacturing costs for the first six months of the fiscal year were ¥32.026 million. The Group's R&D activities were otherwise materially unchanged during the first six months of the fiscal year.」
R&D expenses of ¥32.026 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥15.584 million for the three months ended the first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」
R&D expenses of ¥15.584 million were recorded, and it was stated that there were no material changes in the status of R&D activities. - FY2018RestatedAnnual report
「As a vegetable seedling manufacturer, the Group continues to conduct research and development aimed at developing advanced seedling cultivation technologies and resolving issues with existing technologies.」
The Company continues research and development on advanced seedling cultivation technologies, closed-type seedling cultivation, new grafted seedlings, and seeds and overseas varieties of affiliated companies. Research and development expenses were ¥74.355 million. - FY2018-Q3RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥56.702 million for the nine months ended the third quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」
The Company reported research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2018-Q2RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥36.723 million for the six months ended the second quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」
Research and development expenses of ¥36.723 million were recorded, and the Company stated that there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥14.595 million for the three months ended the first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」
Research and development expenses of ¥14.595 million were recorded, but the Company stated that there were no material changes in the status of its research and development activities. - FY2017RestatedAnnual report
「The Group continues to conduct research and development aimed at developing advanced seedling cultivation technologies and resolving issues with existing technologies. It is also actively developing new seedlings using its vegetable seedling cultivation technologies.」
The Company reaffirmed its policy of continuing research and development and undertaking joint and commissioned research with universities, public research institutions and private companies. Research and development expenses were ¥65.837 million. - FY2017-Q3AdvancedAnnual report
「At a meeting of the Board of Directors held on 31 July 2017, the Company resolved to establish 株式会社むさしのタネ, which was established on 9 August 2017 as described below. The subsidiary was established to engage in a breeding business expected to generate synergies across the Group, including its existing businesses, through the breeding and sale of the Company’s own varieties and the improvement and development of varieties.」
Although it stated that there had been no material changes in research and development activities during the current cumulative quarterly period, the establishment of a subsidiary responsible for breeding and selling the Company’s own varieties and improving and developing varieties was formalized as a subsequent event. - FY2017-Q2RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥34.696 million for the six months ended the second quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」
The Company reported research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2017-Q1RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥16.802 million for the three months ended the first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」
The Company reported research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2016RestatedAnnual report
「As a vegetable seedling manufacturer, the Company continues to conduct research and development aimed at developing new products and seedling cultivation technologies and resolving issues with existing technologies. It has achieved certain results in a wide range of areas, including establishing optimal seedling-growing environments through environmental monitoring of cultivation facilities, improving the productivity of closed-type seedling cultivation and adding value to seedlings, developing new fully closed-type seedling cultivation equipment, and developing new grafted seedlings with high pest and disease control efficacy.」
The Company continues its research and development, covering specific themes including environmental monitoring, closed-type seedling cultivation, new equipment and seedlings designed to control pests and diseases. Research and development expenses were ¥68.423 million. - FY2016-Q3RestatedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥53.166 million for the nine months ended the third quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」
The Company reported total research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2016-Q2First statedAnnual report
「Research and development expenses included in selling, general and administrative expenses and current manufacturing costs totaled ¥37.116 million for the six months ended the second quarter of the current consolidated fiscal year. There were no material changes in the status of the Group’s research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」
The Company reported total research and development expenses for the current cumulative quarterly period and stated that there were no material changes in its research and development activities.